Covid-19 roundup: UK pulls out of billion-dollar vaccine supply deal as nation embraces mix-and-match booster approach
A vaccine agreement between the UK and French biotech Valneva worth $1.65 billion has been abandoned after the country says terms of the deal were not met.
Valneva’s vaccine candidate uses an inactivated virus to invoke an immune response. While that may provide greater coverage against the virus, it can also cause a longer manufacturing timetable. The company announced that Phase III results for VLA2001 were expected in early Q4 2021, and will be a part of the candidate’s submission to the MHRA for approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.